Cargando…
Safety of varenicline as an aid to smoking cessation in professional drivers and its impact on driving behaviors: An observational cohort study of taxi drivers in Beijing
INTRODUCTION: Varenicline is an effective smoking cessation medicine. However, the possible adverse neuropsychiatric events reported by Food and Drug Administration for varenicline may cause safety problems for professional drivers. We aimed to investigate its safety and impacts on driving behaviors...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
European Publishing on behalf of the International Society for the Prevention of Tobacco Induced Diseases (ISPTID)
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7263361/ https://www.ncbi.nlm.nih.gov/pubmed/32494237 http://dx.doi.org/10.18332/tid/120935 |
_version_ | 1783540792797691904 |
---|---|
author | Chu, Shuilian Liang, Lirong Jing, Hang Zhang, Di Tong, Zhaohui |
author_facet | Chu, Shuilian Liang, Lirong Jing, Hang Zhang, Di Tong, Zhaohui |
author_sort | Chu, Shuilian |
collection | PubMed |
description | INTRODUCTION: Varenicline is an effective smoking cessation medicine. However, the possible adverse neuropsychiatric events reported by Food and Drug Administration for varenicline may cause safety problems for professional drivers. We aimed to investigate its safety and impacts on driving behaviors among taxi drivers in Beijing, China. METHODS: An observational cohort study was conducted in a smoking cessation clinic in Beijing, China, between September 2017 and April 2018. Smokers with varenicline for smoking cessation were included and categorized into taxi-driver smokers (n=103) and non-taxi-driver smokers (n=119). All participants received varenicline up to 12 weeks and five standardized counseling sessions. Treatment-related adverse events (AEs) were collected in all participants and their impacts on driving behaviors were assessed in taxi-driver smokers. Multiple logistic regression analysis was used to examine potential risk factors for vareniclinerelated somnolence/fatigue. RESULTS: The incidence of most treatment-related AEs was similar between taxi-driver smokers and non-taxi-driver smokers, but treatment-related somnolence/ fatigue was more frequently reported in taxi-driver smokers (18.4% vs 6.7%; p=0.008). Most taxi-driver smokers (87.4%) reported that treatment-related AEs did not affect their driving behaviors, and no traffic accident was reported during treatment. CONCLUSIONS: Varenicline appears to be a well-tolerated smoking cessation aid for Beijing taxi drivers and has less impact on driving behaviors. However, taxi-driver smokers were more likely to report somnolence/fatigue during varenicline treatment and physicians should pay more attention to this occupational population. |
format | Online Article Text |
id | pubmed-7263361 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | European Publishing on behalf of the International Society for the Prevention of Tobacco Induced Diseases (ISPTID) |
record_format | MEDLINE/PubMed |
spelling | pubmed-72633612020-06-02 Safety of varenicline as an aid to smoking cessation in professional drivers and its impact on driving behaviors: An observational cohort study of taxi drivers in Beijing Chu, Shuilian Liang, Lirong Jing, Hang Zhang, Di Tong, Zhaohui Tob Induc Dis Research Paper INTRODUCTION: Varenicline is an effective smoking cessation medicine. However, the possible adverse neuropsychiatric events reported by Food and Drug Administration for varenicline may cause safety problems for professional drivers. We aimed to investigate its safety and impacts on driving behaviors among taxi drivers in Beijing, China. METHODS: An observational cohort study was conducted in a smoking cessation clinic in Beijing, China, between September 2017 and April 2018. Smokers with varenicline for smoking cessation were included and categorized into taxi-driver smokers (n=103) and non-taxi-driver smokers (n=119). All participants received varenicline up to 12 weeks and five standardized counseling sessions. Treatment-related adverse events (AEs) were collected in all participants and their impacts on driving behaviors were assessed in taxi-driver smokers. Multiple logistic regression analysis was used to examine potential risk factors for vareniclinerelated somnolence/fatigue. RESULTS: The incidence of most treatment-related AEs was similar between taxi-driver smokers and non-taxi-driver smokers, but treatment-related somnolence/ fatigue was more frequently reported in taxi-driver smokers (18.4% vs 6.7%; p=0.008). Most taxi-driver smokers (87.4%) reported that treatment-related AEs did not affect their driving behaviors, and no traffic accident was reported during treatment. CONCLUSIONS: Varenicline appears to be a well-tolerated smoking cessation aid for Beijing taxi drivers and has less impact on driving behaviors. However, taxi-driver smokers were more likely to report somnolence/fatigue during varenicline treatment and physicians should pay more attention to this occupational population. European Publishing on behalf of the International Society for the Prevention of Tobacco Induced Diseases (ISPTID) 2020-05-27 /pmc/articles/PMC7263361/ /pubmed/32494237 http://dx.doi.org/10.18332/tid/120935 Text en © 2020 Chu S. et al. https://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 International License. |
spellingShingle | Research Paper Chu, Shuilian Liang, Lirong Jing, Hang Zhang, Di Tong, Zhaohui Safety of varenicline as an aid to smoking cessation in professional drivers and its impact on driving behaviors: An observational cohort study of taxi drivers in Beijing |
title | Safety of varenicline as an aid to smoking cessation in professional drivers and its impact on driving behaviors: An observational cohort study of taxi drivers in Beijing |
title_full | Safety of varenicline as an aid to smoking cessation in professional drivers and its impact on driving behaviors: An observational cohort study of taxi drivers in Beijing |
title_fullStr | Safety of varenicline as an aid to smoking cessation in professional drivers and its impact on driving behaviors: An observational cohort study of taxi drivers in Beijing |
title_full_unstemmed | Safety of varenicline as an aid to smoking cessation in professional drivers and its impact on driving behaviors: An observational cohort study of taxi drivers in Beijing |
title_short | Safety of varenicline as an aid to smoking cessation in professional drivers and its impact on driving behaviors: An observational cohort study of taxi drivers in Beijing |
title_sort | safety of varenicline as an aid to smoking cessation in professional drivers and its impact on driving behaviors: an observational cohort study of taxi drivers in beijing |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7263361/ https://www.ncbi.nlm.nih.gov/pubmed/32494237 http://dx.doi.org/10.18332/tid/120935 |
work_keys_str_mv | AT chushuilian safetyofvareniclineasanaidtosmokingcessationinprofessionaldriversanditsimpactondrivingbehaviorsanobservationalcohortstudyoftaxidriversinbeijing AT lianglirong safetyofvareniclineasanaidtosmokingcessationinprofessionaldriversanditsimpactondrivingbehaviorsanobservationalcohortstudyoftaxidriversinbeijing AT jinghang safetyofvareniclineasanaidtosmokingcessationinprofessionaldriversanditsimpactondrivingbehaviorsanobservationalcohortstudyoftaxidriversinbeijing AT zhangdi safetyofvareniclineasanaidtosmokingcessationinprofessionaldriversanditsimpactondrivingbehaviorsanobservationalcohortstudyoftaxidriversinbeijing AT tongzhaohui safetyofvareniclineasanaidtosmokingcessationinprofessionaldriversanditsimpactondrivingbehaviorsanobservationalcohortstudyoftaxidriversinbeijing |